(Information sent by the signatory company)
SHANGHAI, Jan. 5, 2023 /PRNewswire/ -- China's innovative pharmaceutical company and CDMO (Contract Development and Manufacturing Organization) Aurisco is cooperating with Cytiva, a global scientific leader, to build its first commercial production Oligo FlexFactory platform. With increased speed and efficiency, Aurisco will be able to supply more oligonucleotides and better serve its customers around the world.
The Oligo FlexFactory platform is the first of three commercial manufacturing lines planned by Aurisco in Yangzhou, eastern China. And this manufacturing plant is expected to produce 200 kilograms of oligonucleotides per year.
Oligonucleotides are synthetic strands of DNA or RNA that can be used as therapeutics or diagnostics by binding to a target gene or protein sequence. Oligonucleotide therapies, such as siRNA (small interfering RNA) and ASO (antisense oligonucleotide), hold promise for the treatment of cancer, Parkinson's disease, and other conditions. According to Research and Markets[1], the global market for oligonucleotide synthesis is expected to reach $16.7 billion by 2027.
Peng Zhi'en, President of Aurisco, explained: "Aurisco is committed to continuous technological innovation that will help our customers deliver better and safer medicines to patients around the world. I believe that the cooperation with Cytiva will facilitate our mission by providing greater speed and efficiency to the commercial production of oligonucleotides".
During this cooperation, Cytiva will offer a comprehensive business solution to Aurisco. It includes an Oligo FlexFactory GMP platform and various technical and support services, such as talent training, manufacturing center process design, as well as project lifecycle management.
It is not the first time that Aurisco collaborates with Cytiva. Previously, with the support of Cytiva's products and services, Aurisco has launched oligonucleotide CRO (Contract Research Organization) and CDMO services at lab and pilot scale in Shanghai.
Going forward, Aurisco and Cytiva will pursue further opportunities for cooperation, accelerating the delivery of life-changing medicines to more patients.
About Aurisco
Established in 1998, Aurisco is an innovative pharmaceutical company dedicated to the research, manufacturing and commercialization of complex APIs, formulations, as well as Oligo CRO/CDMO service. Listed on the Shanghai Stock Exchange in September 2020. Aurisco has been deeply involved in the pharmaceutical industry for more than 20 years and is committed to continuous technological innovation. At present, the company plays a leading role in China in the field of complex synthesis, synthetic biology, photochemistry, etc., and has become a long-term partner of well-known pharmaceutical companies around the world. A complete quality system, sufficient production capacity and a global sales network enable the company to offer high-quality products and efficient service to our customers all over the world.
[1]Research and Markets, noviembre de 2022. https://www.researchandmarkets.com/reports/5312415/global-oligonucleotide-synthesis-market-by.
Photo - https://mma.prnewswire.com/media/1977775...Photo - https://mma.prnewswire.com/media/1977773...Photo - https://mma.prnewswire.com/media/ 1977774...
View original content: https://www.prnewswire.com/news-releases/aurisco-coopera-con-cytiva-para-construir-su-primera-oligo-flexfactory-de-produccion-comercial-301714748.html
